Chi-Med's Surufatinib, Generic Ibrance Among Latest China Approvals

Large Batch Of Late 2020 Nods

China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.

Form close up, fountain pen and approved stamped on a document. Soft focus. - Image
CHINA CONTINUES NEW DRUG APPROVAL SPURT • Source: Shutterstock

On 30 December, China's National Medical Products Administration (NMPA) granted approval to Hutchison China MediTech Limited’s Sulanda (surufatinib) for non-pancreatic neuroendocrine tumors. The vascular endothelial growth factor receptor inhibitor is the second Chi-Med oncology drug to be approved in the country and the first launch for the company in the sector without a partnership. 

In an earlier interview, CEO Christian Hogg had noted the Hong Kong-based company had grown its overall sales nearly 10-fold...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from China

More from Asia